Standard BioTools Inc (LAB) concluded trading on Thursday at a closing price of $1.05, with 5.81 million shares of worth about $6.1 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -52.91% during that period and on May 15, 2025 the price saw a loss of about -1.87%. Currently the company’s common shares owned by public are about 379.09M shares, out of which, 364.89M shares are available for trading.
Stock saw a price change of -5.83% in past 5 days and over the past one month there was a price change of -8.70%. Year-to-date (YTD), LAB shares are showing a performance of -40.00% which decreased to -57.66% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.95 but also hit the highest price of $2.74 during that period. The average intraday trading volume for Standard BioTools Inc shares is 1.56 million. The stock is currently trading -8.08% below its 20-day simple moving average (SMA20), while that difference is down -7.68% for SMA50 and it goes to -35.10% lower than SMA200.
Standard BioTools Inc (NASDAQ: LAB) currently have 379.09M outstanding shares and institutions hold larger chunk of about 73.96% of that.
The stock has a current market capitalization of $398.81M and its 3Y-monthly beta is at 1.53. It has posted earnings per share of -$0.36 in the same period. It has Quick Ratio of 5.37 while making debt-to-equity ratio of 0.07. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for LAB, volatility over the week remained 7.51% while standing at 8.39% over the month.
Analysts are in expectations that Standard BioTools Inc (LAB) stock would likely to be making an EPS of -0.04 in the current quarter, while forecast for next quarter EPS is -0.04 and it is -0.09 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.04 which is -0.04 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.08 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 55.77% while it is estimated to increase by 36.23% in next year. EPS is likely to grow at an annualized rate of 66.44% for next 5-years, compared to annual growth of 11.61% made by the stock over the past 5-years.
Coverage by TD Cowen stated Standard BioTools Inc (LAB) stock as a Buy in their note to investors on April 16, 2024, suggesting a price target of $3.50 for the stock. On April 04, 2024, Jefferies Initiated their recommendations, while on July 12, 2023, KeyBanc Capital Markets Initiated their ratings for the stock with a price target of $4.
